A different approach to the evaluation of the genotype-phenotype relationship in biotinidase deficiency: repeated measurement of biotinidase enzyme activity
Author:
Sürücü Kara İlknur1ORCID, Köse Engin2ORCID, Koç Yekedüz Merve1ORCID, Eminoğlu Fatma Tuba2ORCID
Affiliation:
1. Department of Pediatric Metabolism , Ankara University, Faculty of Medicine , Ankara , Türkiye 2. Department of Pediatric Metabolism , Ankara University Faculty of Medicine, Ankara University Rare Diseases Application and Research Center , Ankara , Türkiye
Abstract
Abstract
Objectives
In the present study, we aimed to evaluate the genotype-phenotype relation in patients with biotinidase enzyme deficiency based on repeated biotinidase enzyme measurements.
Methods
The hospital file information of patients with biotinidase, enzyme deficiency was assessed retrospectively, and the relationship between the BTD gene mutations analysis results and biotinidase enzyme activity following the first and repeated enzyme activity assessments was analyzed.
Results
One-hundred-ten patients were included. In the first enzyme evaluation, profound biotinidase enzyme deficiency was identified in 15 (13.6 %), partial biotinidase enzyme deficiency in 63 (57.3 %), and heterozygous biotinidase enzyme deficiency in 32 (29.1 %) of the patients. The BTD genetic analysis revealed 42 (38.2 %) homozygous, 42 (38.2 %) heterozygous, and 26 (23.6 %) compound heterozygous variants. The most common homozygous variant, p.Asp444His, was evaluated with 130 repeated enzyme measurements and was consistent with a partial biotinidase enzyme deficiency in 55.4 % of cases, heterozygous biotinidase enzyme deficiency in 43.8 % of cases, and profound biotinidase enzyme deficiency in one (0.8 %) case. Clinical symptoms developed in 17 patients during follow-up, of which 70.6 % were related to neurodevelopment. The most common variant was homozygous p.Asp444His (29.4 %) among the patients who developed symptoms.
Conclusions
This is the first study to date to evaluate the genotype-phenotype relationship in patients with biotinidase deficiency through repeated measurements of biotinidase enzyme activity. The study reveals that biotinidase enzyme activity alone is inadequate for diagnosing biotinidase enzyme deficiency or evaluating disease severity, as genetic investigations are also required for a definitive diagnosis of biotinidase enzyme deficiency.
Publisher
Walter de Gruyter GmbH
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology and Child Health
Reference21 articles.
1. Canda, E, Kalkan Uçar, S, Çoker, M. Biotinidase deficiency: prevalence, impact and management strategies. Pediatr Health Med Therapeut 2020;11:127–33. https://doi.org/10.2147/PHMT.S198656. 2. Semeraro, D, Verrocchio, S, Di Dalmazi, G, Rossi, C, Pieragostino, D, Cicalini, I, et al.. High incidence of partial biotinidase deficiency in the first 3 Years of a regional newborn screening program in Italy. Int J Environ Res Publ Health 2022;19:8141. https://doi.org/10.3390/ijerph19138141. 3. Borsatto, T, Sperb-Ludwig, F, Blom, HJ, Schwartz, IVD. Effect of BTD gene variants on in vitro biotinidase activity. Mol Genet Metabol 2019;127:361–7. https://doi.org/10.1016/j.ymgme.2019.07.006. 4. Canda, E, Yazici, H, Er, E, Kose, M, Basol, G, Onay, H, et al.. Single center experience of biotinidase deficiency: 259 patients and six novel mutations. J Pediatr Endocrinol Metab 2018;31:917–26. https://doi.org/10.1515/jpem-2018-0148. 5. Clinvar. https://www.ncbi.nlm.nih.gov/clinvar/?term=BTD%5Bgene%5D&redir=gene.
|
|